The dog that did not bark: malaria vaccines without antibodies

D. Gray Heppner, Robert J. Schwenk, David Arnot, Robert W. Sauerwein, Adrian J. F. Luty

Research output: Contribution to journalArticlepeer-review


To date, the only pre-blood stage vaccine to confer protection against malaria in field trials elicits both antigen-specific antibody and T-cell responses. Recent clinical trials of new heterologous prime-boost malaria vaccine regimens using DNA, fowlpox or MVA, have chiefly elicited T-cell responses that have promisingly reduced hepatic merozoites in challenge trials, but failed to protect in field trials. These encouraging results suggest further augmentation of T-cell responses to pre-blood stage antigens might one day contribute to a highly protective vaccine. We envision that a highly protective pre-erythrocytic vaccine will likely be based upon a heterologous prime-boost regimen that induces both appropriate T-cell responses as well as robust and protracted antibody production.

Original languageEnglish
Pages (from-to)293-296
Number of pages4
JournalTrends in Parasitology
Issue number7
Publication statusPublished - Jul 2007


Dive into the research topics of 'The dog that did not bark: malaria vaccines without antibodies'. Together they form a unique fingerprint.

Cite this